Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Flaherty, Keith
Item TypeName
Academic Article Antisense therapeutics: lessons from early clinical trials.
Academic Article Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Academic Article Advances in drug development. BRAF validation in melanoma.
Academic Article BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
Academic Article EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Academic Article Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
Academic Article Vemurafenib.
Academic Article Narrative review: BRAF opens the door for therapeutic advances in melanoma.
Academic Article Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.
Academic Article Resistance to BRAF-targeted therapy in melanoma.
Academic Article Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.
Academic Article Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
Academic Article Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.
Academic Article BRAF, a target in melanoma: implications for solid tumor drug development.
Academic Article BRAF targeted therapy changes the treatment paradigm in melanoma.
Academic Article New molecular targets in melanoma.
Academic Article COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Academic Article CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Academic Article Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Academic Article Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.
Academic Article Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Academic Article Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Academic Article Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
Academic Article BRAF inhibitors and melanoma.
Academic Article Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Academic Article Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Academic Article New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.
Academic Article Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
Academic Article Is it good or bad to find a BRAF mutation?
Academic Article Improved survival with MEK inhibition in BRAF-mutated melanoma.
Academic Article BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Academic Article Cutaneous effects of BRAF inhibitor therapy: a case series.
Academic Article Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress.
Academic Article p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.
Academic Article BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Academic Article RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Academic Article Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Academic Article Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
Academic Article Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Academic Article MEK and RAF inhibitors for BRAF-mutated cancers.
Academic Article Inhibition of mutated, activated BRAF in metastatic melanoma.
Academic Article Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Academic Article RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Academic Article Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Academic Article Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Academic Article Targeting metastatic melanoma.
Academic Article Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor.
Academic Article Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Academic Article Meeting report from the Third Global Workshop on Melanoma.
Academic Article Biological challenges of BRAF inhibitor therapy.
Academic Article Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
Academic Article Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Concept raf Kinases
Concept Proto-Oncogene Proteins c-raf
Concept Proto-Oncogene Proteins B-raf
Academic Article MAP kinase signaling and inhibition in melanoma.
Academic Article BRAF in melanoma: current strategies and future directions.
Academic Article Elucidating distinct roles for NF1 in melanomagenesis.
Academic Article TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Academic Article Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Academic Article Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
Academic Article CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
Academic Article Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Academic Article MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Academic Article Cyclin-dependent kinases as therapeutic targets in melanoma.
Academic Article Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Academic Article Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Academic Article Commentary: Molecular testing in melanoma.
Academic Article Isolation and molecular characterization of circulating melanoma cells.
Academic Article Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Academic Article PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
Academic Article Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Academic Article Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Academic Article Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.
Academic Article A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Academic Article Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Academic Article The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFa.
Academic Article Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Academic Article Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Academic Article Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
Academic Article Improved overall survival in melanoma with combined dabrafenib and trametinib.
Academic Article Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Academic Article EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Academic Article Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.
Academic Article Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
Academic Article Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Academic Article Universes collide: combining immunotherapy with targeted therapy for cancer.
Academic Article Effectively targeting CRAF: rational serendipity targeting SRC?
Academic Article The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Academic Article Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
Academic Article Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.
Academic Article When are signal transduction targeted therapies acting as immunotherapy?
Academic Article YAP in MAPK pathway targeted therapy resistance.
Academic Article MITF Modulates Therapeutic Resistance through EGFR Signaling.
Academic Article BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Academic Article Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Academic Article Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
Academic Article Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
Academic Article Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Academic Article Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Academic Article BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
Academic Article Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Academic Article Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Academic Article Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Academic Article Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
Academic Article Antitumor Activity of BRAF Inhibitor and IFNa Combination in BRAF-Mutant Melanoma.
Academic Article Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Academic Article Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Academic Article Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Academic Article The Conundrum of Genetic "Drivers" in Benign Conditions.
Academic Article Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Academic Article Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.
Academic Article Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Academic Article MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Academic Article MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Academic Article PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Academic Article An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.
Academic Article Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Academic Article Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
Academic Article Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
Academic Article A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Academic Article BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Academic Article Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Academic Article Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Academic Article PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Academic Article Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Academic Article In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
Academic Article Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
Academic Article Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
Academic Article Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Academic Article Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Academic Article Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Academic Article Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Academic Article A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.
Academic Article ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Academic Article MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas.
Academic Article Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Academic Article Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Academic Article Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.
Academic Article A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors.
Academic Article Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Academic Article Impact of depth of response on survival in patients treated with cobimetinib?±?vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Academic Article Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
Academic Article Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies.
Academic Article Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).
Academic Article Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Academic Article Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Academic Article Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
Academic Article Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib?±?cobimetinib: a pooled analysis of four clinical trials.
Academic Article Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Academic Article Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Academic Article Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.
Academic Article A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
Search Criteria
  • Proto Oncogene Proteins B raf
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.